About Cancer Vaccines
Cancer vaccines are biological preparations that stimulate or strengthen a person’s immune system against cancer. Cancer vaccines are usually administered
intravenously. They can be used in both adults and children. The vaccines can be broadly classified into two: prophylactic and therapeutic vaccines. Prophylactic
vaccines are used for the prevention of cancer, whereas therapeutic vaccines are used for treatment of cancer.
Technavio's analysts forecast the global cancer vaccines market to grow at a CAGR of 27.24% over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019. To calculate the market size, the
report considers revenue generated from the sales of various therapeutic and prophylactic cancer vaccines.
This report covers the present scenario and the growth prospects of the global cancer vaccines market for the period 2015-2019 in the following three regions:
• Americas: The principal countries focused upon in this region are the US, Canada, Mexico, and Brazil
• EMEA: The principal countries focused upon in this region are the UK; Germany; Italy; France; Spain and Middle Eastern and African countries such as Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and UAE
• APAC: The principal countries focused upon in this region are Japan, China, Australia, Singapore, South Korea, and India. APAC is one of the major markets that is
untapped by the leading vendors
The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the market. In addition, it discusses the major drivers that
influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the
market.
Technavio's report, Global Cancer Vaccines Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report
covers the Americas, EMEA, and APAC; it also covers the global cancer vaccines market landscape and its growth prospects in the coming years. The report also includes
a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• Dendreon
• GlaxoSmithKline
• Merck
Other Prominent Vendors
• Aduro BioTech
• Advantagene
• Advaxis
• Agenus
• AlphaVax
• Altor BioScience
• Amgen
• Antigen Express
• Argos Therapeutics
• AVAX Technologies
• Bavarian Nordic
• Biothera
• Bristol-Myers Squibb
• Celldex Therapeutics
• Cel-Sci
• CureVac
• Cytos
• Galena Biopharma
• Genexine
• GlobeImmune
• Gradalis
• Heat Biologics
• Immatics
• ImmunoCellular Therapeutics
• Immutep
• Inovio Pharmaceuticals
• Isa Pharmaceuticals
• Juvaris Biotherapeutics
• MedImmune
• NewLink Genetics
• Northwest Biotherapeutics
• NovaRx
• OncoThyreon
• Oncovir
• Oxford BioMedica
• Prima BioMed
• Progenics
• Provectus Biopharmaceuticals
• Sanofi
• Sotio
• Transgene
• Ubivac
• Vaccinogen
• Vaxon Biotech
• Vical
Market Driver
• Increased Prevalence of Cancers
• For a full, detailed list, view our report
Market Challenge
• Cold Chain Management
• For a full, detailed list, view our report
Market Trend
• Strategic Alliances
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Vaccine Approval Process
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Market Segmentation by Clinical Application of Vaccines
08.1 Prophylactic Vaccines
08.2 Therapeutic Vaccines
09. Global Prophylactic Vaccines Market
09.1.1 Market Overview
09.1.2 Market Size and Forecast
10. Global Therapeutic Vaccines Market
10.1.1 Market Overview
10.1.2 Market Size and Forecast
11. Geographical Segmentation
12. Buying Criteria
13. Key Brand Analysis
13.1 Comparative Study between Gardasil and Cervarix
14. Pipeline Portfolio
14.1.1 Prostvac
14.1.2 Neuvax
14.1.3 Rindopepimut
14.1.4 MVax
14.1.5 DCVax-L
14.1.6 ProstAtak
14.1.7 Talimogene Laherparepvec
14.1.8 IMA901
14.1.9 Imprime PGG
14.1.10 OncoVAX
14.1.11 Lucanix
14.1.12 DCVACPCa
15. Market Growth Drivers
16. Drivers and their Impact
17. Market Challenges
18. Impact of Drivers and Challenges
19. Market Trends
20. Trends and their Impact
21. Vendor Landscape
21.1 Competitive Scenario
21.1.1 Key News
21.1.2 Mergers and Acquisitions
21.2 Market Share Analysis 2014
21.2.1 Merck
21.2.2 Dendreon
21.2.3 GlaxoSmithKline
21.3 Other and Future Prominent Vendors
22. Opportunities for Cancer Vaccine Vendors
23. Key Vendor Analysis
23.1 Dendreon
23.1.1 Key Facts
23.1.2 Business Overview
23.1.3 Recent Developments
23.1.4 SWOT Analysis
23.2 GlaxoSmithKline
23.2.1 Key facts
23.2.2 Business overview
23.2.3 Business segmentation by revenue 2014
23.2.4 Business segmentation by revenue 2013 and 2014
23.2.5 Geographical segmentation by revenue 2014
23.2.6 Business strategy
23.2.7 Recent developments
23.2.8 SWOT analysis
23.3 Merck & Co. Inc.
23.3.1 Key Facts
23.3.2 Business Overview
23.3.3 Business Segmentation by Revenue 2013
23.3.4 Business Segmentation by Revenue 2012 and 2013
23.3.5 Sales by Geography
23.3.6 Business Strategy
23.3.7 Key Developments
23.3.8 SWOT Analysis
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Vaccine Approval Process
Exhibit 3: Global Cancer Vaccines Market 2014-2019 ($ millions)
Exhibit 4: Segmentation of Global Cancer Vaccines Market by Clinical Application of Vaccines
Exhibit 5: Segmentation of Global Cancer Vaccines Market by Clinical Application of Vaccines, 2014
Exhibit 6: Global Prophylactic Vaccines Market 2014-2019 ($ millions)
Exhibit 7: Global Therapeutic Vaccines Market 2014-2019 ($ millions)
Exhibit 8: Segmentation of the Global Cancer Vaccines Market by Geography, 2014
Exhibit 9: Global Cancer Vaccines Market: Comparison of the Major Brands
Exhibit 10: Gardasil and Cervarix: A Comparative Study
Exhibit 11: Key Late-stage Vaccines Under Development
Exhibit 12: Drivers of the Global Cancer Vaccines Market
Exhibit 13: Challenges of the Global Cancer Vaccines Market
Exhibit 14: Trends of the Global Cancer Vaccines Market
Exhibit 15: Global Revenue and YoY Growth Rate of Gardasil 2010-2014
Exhibit 16: Global Revenue and YoY Growth Rate of Provenge 2011-2014
Exhibit 17: Global Revenue and YoY Growth Rate of Cervarix 2010-2014
Exhibit 18: Opportunity Analysis: Global Cancer Vaccine Market
Exhibit 19: GlaxoSmithKline: Business segmentation by revenue 2014
Exhibit 20: GlaxoSmithKline: Business segmentation by revenue 2013 and 2014 ($ billion)
Exhibit 21: GlaxoSmithKline: Geographical segmentation by revenue 2014
Exhibit 22: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 23: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 24: Merck & Co. Inc.: Sales by Geography 2013
